Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Neuroendocrine Tumors Clinical Practice Guidelines in Oncology JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Kulke, M. H., Benson, A. B., Bergsland, E., Berlin, J. D., Blaszkowsky, L. S., Choti, M. A., Clark, O. H., Doherty, G. M., Eason, J., Emerson, L., Engstrom, P. F., Goldner, W. S., Heslin, M. J., Kandeel, F., Kunz, P. L., Kuvshinoff, B. W., Moley, J. F., Pillarisetty, V. G., Saltz, L., Schteingart, D. E., Shah, M. H., Shibata, S., Strosberg, J. R., Vauthey, J., White, R., Yao, J. C., Freedman-Cass, D. A., Dwyer, M. A. 2012; 10 (6): 724-764

Abstract

Neuroendocrine tumors comprise a broad family of tumors, the most common of which are carcinoid and pancreatic neuroendocrine tumors. The NCCN Neuroendocrine Tumors Guidelines discuss the diagnosis and management of both sporadic and hereditary neuroendocrine tumors. Most of the recommendations pertain to well-differentiated, low- to intermediate-grade tumors. This updated version of the NCCN Guidelines includes a new section on pathology for diagnosis and reporting and revised recommendations for the surgical management of neuroendocrine tumors of the pancreas.

View details for Web of Science ID 000304889700006